Lenvatinib Mesilate APIs are a cornerstone of Loncom Pharma's oncology portfolio, used in therapies that target various receptor tyrosine kinases implicated in tumor growth. These APIs enable the development of drugs that can significantly extend the lives of cancer patients.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
